INDICATIONS FOR USE Use Level of Chlortetracycline lbs. of Pennchlor 100 Hi-Flo ® per ton Approved by FDA under NADA # 138-935 Pennchlor 100 Hi-Flo® is a registered trademark of Pharmgate Inc. Chickens For Chickens: Control of infectious synovitis caused by Mycoplasma synoviae susceptible to chlortetracycline. (Feed continuously for 7 - 14 days) 100-200 g/ton 1.0 – 2.0 WARNING: DO NOT FEED TO CHICKENS PRODUCING EG...
Chlortetracyline
Type A Medicated Article
Active Drug Ingredients: Chlortetracycline as Chlortetracycline Calcium Complex equivalent to 100 grams Chlortetracycline Hydrochloride/lb.
Ingredients: Chlortetracycline, Calcium Carbonate, Roughage Products and Mineral Oil.
For Use in the Manufacture of Medicated Feeds.
CAUTION: For use in Dry Feeds ONLY. NOT FOR USE IN LIQUID FEED SUPPLEMENTS
| INDICATIONS FOR USE | Use Level of Chlortetracycline | lbs. of Pennchlor 100 Hi-Flo® per ton |
|---|---|---|
| Approved by FDA under NADA # 138-935 | ||
| Pennchlor 100 Hi-Flo® is a registered trademark of Pharmgate Inc. | ||
| Chickens | ||
| For Chickens: Control of infectious synovitis caused by Mycoplasma synoviae susceptible to chlortetracycline. (Feed continuously for 7 - 14 days) | 100-200 g/ton | 1.0 – 2.0 |
| WARNING: DO NOT FEED TO CHICKENS PRODUCING EGGS FOR HUMAN CONSUMPTION. ZERO-DAY WITHDRAWAL PERIOD. | ||
| For Chickens: Control of chronic respiratory disease (CRD) and air sac infection caused by Mycoplasma gallisepticum and Escherichia coli susceptible to chlortetracycline. (Feed continuously for 7 - 14 days). | 200-400 g/ton | 2.0 – 4.0 |
| WARNING: DO NOT FEED TO CHICKENS PRODUCING EGGS FOR HUMAN CONSUMPTION. ZERO-DAY WITHDRAWAL PERIOD. | ||
| For Chickens: Reduction of mortality due to Escherichia coli infections susceptible to chlortetracycline (Feed for 5 days). | 500 g/ton | 5.0 |
| WARNING: DO NOT FEED TO CHICKENS PRODUCING EGGS FOR HUMAN CONSUMPTION. WITHDRAW 24 HOURS PRIOR TO SLAUGHTER. | ||
| Turkeys | ||
| For Turkeys: Control of infectious synovitis caused by Mycoplasma synoviae susceptible to chlortetracycline (Feed continuously for 7 - 14 days) | 200 g/ton | 2.0 |
| WARNING: DO NOT FEED TO TURKEYS PRODUCING EGGS FOR HUMAN CONSUMPTION. ZERO-DAY WITHDRAWAL PERIOD. | ||
| For Turkeys: Control of hexamitiasis caused by Hexamita meleagrides susceptible to chlortetracycline. (Feed continuously for 7 - 14 days). | 400 g/ton | 4.0 |
| WARNING: DO NOT FEED TO TURKEYS PRODUCING EGGS FOR HUMAN CONSUMPTION. ZERO-DAY WITHDRAWAL PERIOD. | ||
| For Turkeys: Turkey poults not over 4 weeks of age: Reduction of mortality due to paratyphoid caused by Salmonella typhimurium susceptible to chlortetracycline. | 400 g/ton | 4.0 |
| For Turkeys: Control of complicating bacterial organisms associated with bluecomb (transmissible enteritis, coronaviral enteritis) susceptible to chlortetracycline. (Feed continuously for 7 - 14 days) | 25 mg/lb body weight/day | |
| WARNING: DO NOT FEED TO TURKEYS PRODUCING EGGS FOR HUMAN CONSUMPTION. ZERO-DAY WITHDRAWAL PERIOD. | ||
| Swine | ||
| For Swine: Reducing the incidence of cervical lymphadenitis (jowl abscesses) caused by Group E Streptococci susceptible to chlortetracycline. | 50-100 g/ton | 0.5 – 1.0 |
| For Breeding Swine: Control of leptospirosis (reducing the instances of abortions and shedding of leptospirae) caused by Leptospira pomona susceptible to chlortetracycline. (Feed continuously for not more than 14 days) | 400 g/ton | 4.0 |
| For Swine: Treatment of bacterial enteritis caused by Escherichia coli and Salmonella choleraesuis and bacterial pneumonia caused by Pasteurella multocida susceptible to chlortetracycline. (Feed for not more than 14 days.) | Feed approximately 400 g/t, varying with body weight and feed consumption to provide 10 mg/lb body weight/day. | |
| WARNING: ZERO-DAY WITHDRAWAL PERIOD. | ||
| CALVES, BEEF CATTLE, AND NONLACTATING DAIRY CATTLE | ||
| WARNING: A WITHDRAWAL PERIOD HAS NOT BEEN ESTABLISHED FOR THIS PRODUCT IN PRE-RUMINATNG CALVES. DO NOT USE IN CALVES TO BE PROCESSED FOR VEAL. | ||
| For Growing Cattle (over 400 lbs.): For the reduction of the incidence of liver abscesses. | 70 mg/head/day | |
| WARNING: ZERO-DAY WITHDRAWAL PERIOD. | ||
| For Beef Cattle: For the control of bacterial pneumonia associated with shipping fever complex caused by Pasteurella spp. susceptible to chlortetracycline | 350 mg/head/day | |
| WARNING: ZERO-DAY WITHDRAWAL PERIOD. | ||
| For Beef Cattle (under 700 lbs.): Control of active infection of anaplasmosis caused by Anaplasma marginale susceptible to chlortetracycline. | 350 mg/head/day | |
| WARNING: ZERO-DAY WITHDRAWAL PERIOD. | ||
| For Beef Cattle (over 700 lbs.): Control of active infection of anaplasmosis caused by Anaplasma marginale susceptible to chlortetracycline. | 0.5 mg/ lb. body weight/day | |
| WARNING: ZERO-DAY WITHDRAWAL PERIOD. | ||
| For Calves, Beef, and Nonlactating Dairy Cattle: For treatment of bacterial enteritis caused by Escherichia coli and bacterial pneumonia caused by Pasteurella multocida susceptible to chlortetracycline. (Treat for not more than 5 days) | 10 mg/lb. body weight/day | |
| WARNING: ZERO-DAY WITHDRAWAL PERIOD. | ||
| Sheep | ||
| For Breeding Sheep: Reducing the incidence of (vibrionic) abortion caused by Campylobacter fetus infection susceptible to chlortetracycline. | 80 mg/head/day | |
| WARNING: ZERO-DAY WITHDRAWAL PERIOD. | ||
Marketed by:
Pharmgate Animal Health, LLC
14040 Industrial Road
Omaha, NE 68144
Take Time
Pennchlor® 100 Hi-Flo™
Chlortetracycline
Type A Medicated Article
CAUTION: Federal law restricts medicated feed containing this
veterinary feed directive (VFD) drug to use by or on the order of a
licensed veterinarian.
See mixing directions, claims, cautions and warnings on back.
Restricted Drug (California) - Use Only as Directed.
Not For Human Use.
Net wt. 50 LB (22.68 Kg)
Pharmgate
ANIMAL HEALTH
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 51429-102-01 | Pennchlor 100 Hi-Flo | 22.68 kg in 1 BAG | POWDER | 22.68 | 5 |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| Chlortetracycline Calcium | ACTIVE INGREDIENT | NR4B2SX17S | 1 | |
| Chlortetracycline | ACTIVE MOIETY | WCK1KIQ23Q | 1 | |
| Calcium Carbonate | INACTIVE INGREDIENT | H0G9379FGK | 1 | |
| Mineral Oil | INACTIVE INGREDIENT | T5L8T28FGP | 1 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 51429-102 | 51429-102-01 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| Chlortetracycline Calcium | NR4B2SX17S | ACTIR |
| Calcium Carbonate | H0G9379FGK | IACT |
| Mineral Oil | T5L8T28FGP | IACT |
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| Mineral Oil | MINERAL OIL | T5L8T28FGP | LOTION / TOPICAL | 1428 mg | ||
| Mineral Oil | MINERAL OIL | T5L8T28FGP | PASTE / DENTAL | 95 %w/w | ||
| Mineral Oil | MINERAL OIL | T5L8T28FGP | GEL / TOPICAL | 2.5 %w/w | ||
| Mineral Oil | MINERAL OIL | T5L8T28FGP | OINTMENT / AURICULAR (OTIC) | NA | ||
| Calcium Carbonate | CALCIUM CARBONATE | H0G9379FGK | TABLET, EXTENDED RELEASE / ORAL | 229.7 mg | ||
| Calcium Carbonate | CALCIUM CARBONATE | H0G9379FGK | CAPSULE, DELAYED RELEASE / ORAL | 20 mg | ||
| Calcium Carbonate | CALCIUM CARBONATE | H0G9379FGK | CAPSULE, EXTENDED RELEASE / ORAL | 4 mg | ||
| Calcium Carbonate | CALCIUM CARBONATE | H0G9379FGK | SOLUTION / RESPIRATORY (INHALATION) | 4.02 %w/v | ||
| Mineral Oil | MINERAL OIL | T5L8T28FGP | FILM, EXTENDED RELEASE / TRANSDERMAL | 34 mg | ||
| Mineral Oil | MINERAL OIL | T5L8T28FGP | SPRAY / TOPICAL | 1379 mg | ||
| Mineral Oil | MINERAL OIL | T5L8T28FGP | SUSPENSION / TOPICAL | 82 %w/w | ||
| Mineral Oil | MINERAL OIL | T5L8T28FGP | SUPPOSITORY / RECTAL | NA | ||
| Calcium Carbonate | CALCIUM CARBONATE | H0G9379FGK | FILM, SOLUBLE / ORAL | 14 mg | ||
| Mineral Oil | MINERAL OIL | T5L8T28FGP | DROPS / ORAL | NA | ||
| Mineral Oil | MINERAL OIL | T5L8T28FGP | SYSTEM / TRANSDERMAL | 6.09 mg | ||
| Mineral Oil | MINERAL OIL | T5L8T28FGP | TABLET, CHEWABLE / ORAL | 6 mg | ||
| Mineral Oil | MINERAL OIL | T5L8T28FGP | CREAM / VAGINAL | 402 mg | ||
| Mineral Oil | MINERAL OIL | T5L8T28FGP | TABLET, EXTENDED RELEASE / ORAL | NA | ||
| Mineral Oil | MINERAL OIL | T5L8T28FGP | SUSPENSION / OPHTHALMIC | 0.1 %w/w | ||
| Calcium Carbonate | CALCIUM CARBONATE | H0G9379FGK | GUM, CHEWING / BUCCAL | 3492 mg | ||
| Mineral Oil | MINERAL OIL | T5L8T28FGP | CAPSULE, EXTENDED RELEASE / ORAL | 120 mg | ||
| Calcium Carbonate | CALCIUM CARBONATE | H0G9379FGK | TABLET, DELAYED RELEASE / ORAL | 8.4 mg | ||
| Mineral Oil | MINERAL OIL | T5L8T28FGP | PASTE / TOPICAL | 47.5 %w/w | ||
| Mineral Oil | MINERAL OIL | T5L8T28FGP | OIL / TOPICAL | 43.29 %v/v | ||
| Mineral Oil | MINERAL OIL | T5L8T28FGP | TABLET / ORAL | 113.75 mg | ||
| Mineral Oil | MINERAL OIL | T5L8T28FGP | TABLET, COATED / ORAL | 1.5 mg | ||
| Mineral Oil | MINERAL OIL | T5L8T28FGP | SUPPOSITORY / VAGINAL | 30 mg | ||
| Mineral Oil | MINERAL OIL | T5L8T28FGP | OINTMENT / TOPICAL | 9938 mg | ||
| Mineral Oil | MINERAL OIL | T5L8T28FGP | FILM / TRANSDERMAL | 11.42 mg | ||
| Mineral Oil | MINERAL OIL | T5L8T28FGP | SUSPENSION / AURICULAR (OTIC) | 0.5 %w/v | ||
| Mineral Oil | MINERAL OIL | T5L8T28FGP | CREAM / TOPICAL | 2772 mg | ||
| Calcium Carbonate | CALCIUM CARBONATE | H0G9379FGK | SOLUTION / AURICULAR (OTIC) | 0.38 %w/w | ||
| Calcium Carbonate | CALCIUM CARBONATE | H0G9379FGK | TABLET, FILM COATED / ORAL | 300 mg | ||
| Calcium Carbonate | CALCIUM CARBONATE | H0G9379FGK | TABLET, CHEWABLE / ORAL | 1650 mg | ||
| Mineral Oil | MINERAL OIL | T5L8T28FGP | CAPSULE / ORAL | 120 mg | ||
| Calcium Carbonate | CALCIUM CARBONATE | H0G9379FGK | TABLET, COATED / ORAL | 64.8 mg | ||
| Mineral Oil | MINERAL OIL | T5L8T28FGP | OINTMENT / OPHTHALMIC | 59.5 %w/w | ||
| Calcium Carbonate | CALCIUM CARBONATE | H0G9379FGK | SOLUTION / INTRAVENOUS | 4.02 %w/v | ||
| Mineral Oil | MINERAL OIL | T5L8T28FGP | SOAP / TOPICAL | 0.82 %w/w | ||
| Mineral Oil | MINERAL OIL | T5L8T28FGP | TABLET, FILM COATED / ORAL | NA | ||
| Mineral Oil | MINERAL OIL | T5L8T28FGP | SYSTEM / TOPICAL | 654.36 mg | ||
| Calcium Carbonate | CALCIUM CARBONATE | H0G9379FGK | TABLET / ORAL | 793 mg | ||
| Mineral Oil | MINERAL OIL | T5L8T28FGP | TABLET, DELAYED RELEASE / ORAL | 5.67 mg | ||
| Calcium Carbonate | CALCIUM CARBONATE | H0G9379FGK | CAPSULE / ORAL | 349.9 mg | ||
| Calcium Carbonate | CALCIUM CARBONATE | H0G9379FGK | POWDER, DENTIFRICE / DENTAL | 0.5 mg/mg |
Adverse event summaries are temporarily unavailable. Other product information remains available.